# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-22-047496
Filing Date
2022-08-12
Accepted
2022-08-12 17:01:31
Documents
50
Period of Report
2022-06-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | QUARTERLY REPORT | f10q0622_actiniumpharma.htm iXBRL | 10-Q | 812113
2 | EXCLUSIVE LICENSE AND SUPPLY AGREEMENT, DATED APRIL 7, 2022, BETWEEN IMMEDICA PH | f10q0622ex10-1_actinium.htm | EX-10.1 | 346333
3 | SUBLEASE AGREEMENT, DATED APRIL 28, 2022, BETWEEN ABN AMRO HOLDINGS USA LLC AND | f10q0622ex10-2_actinium.htm | EX-10.2 | 80291
4 | CERTIFICATION | f10q0622ex31-1_actinium.htm | EX-31.1 | 10655
5 | CERTIFICATION | f10q0622ex31-2_actinium.htm | EX-31.2 | 11175
6 | CERTIFICATION | f10q0622ex32-1_actinium.htm | EX-32.1 | 4401
7 | CERTIFICATION | f10q0622ex32-2_actinium.htm | EX-32.2 | 4755
| Complete submission text file | 0001213900-22-047496.txt |  | 3866748

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
8 | XBRL SCHEMA FILE | atnm-20220630.xsd | EX-101.SCH | 38314
9 | XBRL CALCULATION FILE | atnm-20220630_cal.xml | EX-101.CAL | 22969
10 | XBRL DEFINITION FILE | atnm-20220630_def.xml | EX-101.DEF | 145678
11 | XBRL LABEL FILE | atnm-20220630_lab.xml | EX-101.LAB | 337088
12 | XBRL PRESENTATION FILE | atnm-20220630_pre.xml | EX-101.PRE | 157485
44 | EXTRACTED XBRL INSTANCE DOCUMENT | f10q0622_actiniumpharma_htm.xml | XML | 281731

Mailing Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016
Business Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016 646-677-3875
Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)

EIN.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36374 | Film No.: 221161054
SIC: 2834 Pharmaceutical Preparations